Maurice D H, Haslam R J
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Mol Pharmacol. 1990 May;37(5):671-81.
We investigated the roles of cyclic GMP and cyclic AMP in the inhibition of rabbit platelet aggregation and degranulation by two nitrovasodilators, sodium nitroprusside (SNP) and 3-morpholinosydnonimine (SIN-1; the active metabolite of molsidomine), with particular reference to the synergistic interaction of these drugs with prostaglandin E1 (PGE1). Changes in platelet cyclic [3H]GMP and cyclic [3H]AMP were measured by rapid and sensitive prelabeling techniques, the validity of which were confirmed by radioimmunoassays. Incubation of the platelets with 0.1 to 10 microM SNP alone for 0.5 min caused progressively greater inhibitions of platelet function associated with large dose-dependent increases in cyclic [3H]GMP and 1.4- to 3.0-fold increases in cyclic [3H]AMP. However, addition of SNP with the adenylate cyclase activator, PGE1, at a concentration of the latter that had little effect alone, caused much larger increases in cyclic [3H]AMP and greatly enhanced the inhibition of platelet aggregation. SIN-1 had effects similar to those of SNP, although it was less active. The adenylate cyclase inhibitor 2',5'-dideoxyadenosine (DDA) diminished the increases in cyclic [3H]AMP caused by SNP or SIN-1 in both the presence and absence of PGE1 but reduced the inhibition of platelet function caused by the nitrovasodilators only in the presence of PGE1. These results suggest that, although cyclic GMP may mediate the inhibition of rabbit platelet function by high concentrations of nitrovasodilators added alone, the synergistic interaction of lower concentrations with PGE1 depends on an enhanced accumulation of cyclic AMP. Synergistic effects on cyclic [3H]AMP accumulation were also observed on incubation of platelets with SNP and adenosine, another activator of adenylate cyclase. Hemoglobin, which binds nitric oxide, blocked or reversed the increases in both cyclic [3H]GMP and cyclic [3H]AMP in platelets caused by the nitrovasodilators added either alone or with PGE1. Cilostamide, a selective inhibitor of platelet low Km cyclic AMP phosphodiesterase, had effects on platelet cyclic [3H]AMP accumulation identical to those of SNP, suggesting that the action of the latter depends on inhibition of the same enzyme. M&B 22,948, a selective inhibitor of cyclic GMP phosphodiesterase, potentiated the increases in both cyclic [3H]GMP and cyclic [3H]AMP caused by SNP. A hyperbolic relationship was found between the increases in cyclic [3H]GMP and cyclic [3H]AMP caused by different concentrations of SNP; this relationship was not affected by addition of M&B 22,948. The results strongly suggest that the increases in platelet cyclic [3H]AMP caused by nitrovasodilators in the presence or absence of activators of adenylate cyclase are mediated by the inhibition by cyclic GMP of cyclic AMP breakdown.(ABSTRACT TRUNCATED AT 400 WORDS)
我们研究了环鸟苷酸(cGMP)和环腺苷酸(cAMP)在两种硝基血管扩张剂——硝普钠(SNP)和3-吗啉代西多明(SIN-1;莫西多明的活性代谢产物)抑制兔血小板聚集和脱颗粒过程中的作用,特别关注了这些药物与前列腺素E1(PGE1)的协同相互作用。通过快速灵敏的预标记技术测定血小板中环[3H]GMP和环[3H]AMP的变化,放射免疫测定法证实了该技术的有效性。血小板与0.1至10微摩尔/升的SNP单独孵育0.5分钟,会逐渐增强对血小板功能的抑制作用,这与环[3H]GMP的大量剂量依赖性增加以及环[3H]AMP 1.4至3.0倍的增加相关。然而,在腺苷酸环化酶激活剂PGE1单独作用效果甚微的浓度下,加入SNP会使环[3H]AMP大幅增加,并极大增强对血小板聚集的抑制作用。SIN-1的作用与SNP相似,尽管其活性较低。腺苷酸环化酶抑制剂2',5'-二脱氧腺苷(DDA)在有或无PGE1的情况下,均可减少SNP或SIN-1引起的环[3H]AMP增加,但仅在有PGE1时降低硝基血管扩张剂对血小板功能的抑制作用。这些结果表明,尽管高浓度单独添加的硝基血管扩张剂可能通过cGMP介导对兔血小板功能的抑制,但较低浓度与PGE1的协同相互作用取决于cAMP积累的增强。在血小板与SNP和腺苷(另一种腺苷酸环化酶激活剂)孵育时,也观察到对环[3H]AMP积累的协同作用。血红蛋白可结合一氧化氮,能阻断或逆转单独添加或与PGE1一起添加的硝基血管扩张剂引起的血小板中环[3H]GMP和环[3H]AMP的增加。西洛酰胺是血小板低Km环AMP磷酸二酯酶的选择性抑制剂,对血小板环[3H]AMP积累的作用与SNP相同,表明后者的作用取决于对同一种酶的抑制。M&B 22,948是环GMP磷酸二酯酶的选择性抑制剂,可增强SNP引起的环[3H]GMP和环[3H]AMP的增加。发现不同浓度SNP引起的环[3H]GMP和环[3H]AMP增加之间呈双曲线关系;添加M&B 22,948不影响这种关系。结果强烈表明,无论有无腺苷酸环化酶激活剂,硝基血管扩张剂引起的血小板中环[3H]AMP增加是由cGMP对环AMP分解的抑制介导的。(摘要截于400字)